Fidelity SPDR Advertisement
Home > Boards > US OTC > Medical - Drugs >

Cellceutix Corporation (CTIX)

CTIX RSS Feed
Add CTIX Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator BigKahuna, BooDog, KarinCA, noretreat, TOB, starbuxsux
Search This Board:
Last Post: 11/23/2014 1:09:27 PM - Followers: 505 - Board type: Free - Posts Today: 47

Cellceutix Corporation (CTIX) 
 

 

http://cellceutix.com/
 

 
Company Address:
100 Cumming Center, Suite 151-B
Beverly, MA 01915
Phone: 978-236-8717
Fax:  978-921-6564
Email:  info@cellceutix.com
 
CIK:  0001355250
 
Cellceutix is a publicly traded company under the symbol “CTIX”. Cellceutix is a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology and antibiotic applications. Cellceutix believes it has a world-class portfolio of compounds and is now engaged in advancing its compounds and seeking strategic partnerships. Cellceutix’s anti-cancer drug Kevetrin is currently in a Phase 1 clinical trial at Harvard Cancer Centers’ Dana Farber Cancer Institute and Beth Israel Deaconess Medical Center. In the laboratory Kevetrin has shown to induce activation of p53, often referred to as the “Guardian Angel Gene” due to its crucial role in controlling cell mutations. Cellceutix is planning a Phase 2 clinical trial with its novel compound Brilacidin-OM for the prevention and treatment of Oral Mucositis. Brilacidin-OM, a defensin mimetic compound, has shown in the laboratory to reduce the occurrence of severe ulcerative oral mucositis by more than 94% compared to placebo. Cellceutix’s anti-psoriasis drug Prurisol is presently in a bioequivalence crossover clinical trial in Miami, FL. Prurisol is a small molecule that acts through immune modulation and PRINS reduction. Cellceutix’s key antibiotic, Brilacidin, is in a Phase 2b trial for Acute Bacterial Skin and Skin Structure Infections, or ABSSSI. Brilacidin has the potential to be a single-dose therapy or a dosing regimen that is shorter than currently marketed antibiotics for multi-drug resistant bacteria (Superbugs). Cellceutix has formed research collaborations with world-renowned research institutions in the United States and Europe, including MD Anderson Cancer Center, Beth Israel Deaconess Medical Center, and the University of Bologna.

 

Management:   http://cellceutix.com/team/
The above link is kept updated.

 
Ongoing Human Trials:  http://clinicaltrials.gov/ct2/results?term=Cellceutix+Pharmaceuticals&Search=Search
 
Product Pipeline:  http://cellceutix.com/pipeline/
 

 
Recent News and Press Releases: 
http://finance.yahoo.com/q/h?s=CTIX+Headlines

Seeking Alpha focus articles on CTIX: http://seekingalpha.com/symbol/CTIX
 
http://cellceutix.com/category/press-release/
 
SEC Filings:  http://www.sec.gov/cgi-bin/browse-edgar?company=Cellceutix+Corp&match=&CIK=ctix&filenum=&State=&Country=&SIC=&owner=exclude&Find=Find+Companies&action=getcompany

Transfer Agent:
West Coast Stock Transfer, Inc.
721 N. Vulcan Ave. Ste. 205
Encinitas, CA 92024
(619) 664-4780 p
(760) 452-4423 f
cs@wcsti.com
http://www.westcoaststocktransfer.com/

 
Share Structure:  See SEC filing link above for current share structure
 

Cellceutix IP - Patent Filings:
EPO
http://worldwide.espacenet.com/searchResults?PA=Cellceutix&DB=EPODOC&locale=en_EP&ST=advanced&compact=false
WIPO
http://www.wipo.int/patentscope/search/en/detail.jsf?docId=WO2010135170&recNum=1&docAn=US2010034838&queryString=FP:(Cellceutix)&maxRec=1
USPTO
http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=0&f=S&l=50&TERM1=Cellceutix&FIELD1=AS&co1=AND&TERM2=&FIELD2=&d=PG01 


http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=8,796,275.PN.&OS=PN/8,796,275&RS=PN/8,796,275
 

Publication number US8338454 B2
Publication type Grant
Application number US 12/780,132
Publication date Dec 25, 2012
Filing date May 14, 2010
Priority date May 20, 2009
Also published as CA2762427A1, CN102438612A, EP2432464A2, US20100298374, US20130245062, WO2010135170A2, WO2010135170A3, Less «6 More »
Publication number 12780132, 780132, US 8338454 B2, US 8338454B2, US-B2-8338454, US8338454 B2, US8338454B2
Inventors Krishna Menon
Original Assignee Cellceutix Corporation
Export Citation BiBTeX, EndNote, RefMan
Patent Citations (6), Non-Patent Citations (41), Referenced by (1), Classifications (42)
 
External Links: USPTO, USPTO Assignment, Espacenet


http://www.google.com/patents/US8338454

http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=6&f=G&l=50&co1=AND&d=PG01&s1=Cellceutix.AS.&OS=AN/Cellceutix&RS=AN/Cellceutix

 
Investor Relations:  info@cellceutix.com

Following is a WEEKLY chart:


 
 


 
 
All messages, including iBox content, are the opinion of the posters, are no substitute for your own research, and should not be relied upon for stock trading or any other purpose.
 
Also, keep in mind that moderators may or may not have a position in said stock.  Being a moderator isn’t a sign of endorsement.
 
Please keep your posts on topic because your message(s) will probably be deleted when:
* Posting content that's off-topic to the subject of this board;
* Posting statements that don't add value to the discussion; or
* When you violate any other posting term of the iHub User Agreement: http://investorshub.advfn.com/boards/complex_terms.asp

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
CTIX
Current Price
Volume:
Bid Ask Day's Range
Wiki
CTIX News: Notice of Effectiveness (effect) 11/19/2014 06:01:25 AM
CTIX News: Securities Registration Statement (simplified Form) (s-3/a) 11/10/2014 05:31:51 PM
CTIX News: Securities Registration Statement (simplified Form) (s-3) 10/30/2014 04:31:15 PM
CTIX News: Current Report Filing (8-k) 10/24/2014 06:04:28 AM
CTIX News: ALTITRADE PARTNERS™ SAYS A KEY-REVERSAL DAY COULD HAPPEN THIS WEEK 10/14/2014 06:00:00 AM
PostSubject
#77645  Sticky Note Cellceutix Makes Breakthrough in Cancer Research by Activating BigKahuna 11/11/14 08:36:44 AM
#77615  Sticky Note Kevetrin AND Brilacidin-OM news. Patient Enrollment in Cellceutix BooDog 11/11/14 04:24:03 AM
#74575  Sticky Note Cellceutix Announces Positive Top-Line Data From Phase 2b TOB 10/23/14 11:59:10 AM
#67831  Sticky Note $CTIX News, SEC filings, FDA trials, misc., and KarinCA 09/03/14 06:13:02 PM
#57289  Sticky Note Cellceutix Initiates Clinical Trial of Prurisol as New starbuxsux 03/25/14 09:02:21 AM
#79296   Yummy! TheDane 11/23/14 01:24:02 PM
#79295   I'll work on that tonight and let you TheDane 11/23/14 01:23:19 PM
#79294   I agree Ultimate01. JPsooner 11/23/14 01:09:27 PM
#79293   It is not a MUST to use late sox040713 11/23/14 12:45:26 PM
#79292   Glen Morangie...sherry cask finished...12 yrs minimum. scgmck1 11/23/14 12:43:28 PM
#79291   George, it's a silly argument. Kevetrin is nearing biodoc 11/23/14 12:19:18 PM
#79290   I think I'm simply going to wait for KarinCA 11/23/14 12:16:19 PM
#79289   I took him off "ignore" just to see scgmck1 11/23/14 12:04:09 PM
#79288   Apparition Wishing you a great Thanksgiving Holiday. georgejjl 11/23/14 12:03:36 PM
#79287   Prurisol could be a blockbuster selling drug with georgejjl 11/23/14 12:00:40 PM
#79286   If B-OM will be a rinse, would it F1ash 11/23/14 11:49:28 AM
#79285   For the record. I'm not angry ;). Even Apparition 11/23/14 11:44:27 AM
#79284   There is no need for anger. georgejjl 11/23/14 11:39:38 AM
#79282   Jpsooner, I agree with that. I also hold Ultimate01 11/23/14 11:35:39 AM
#79278   Apparition: Thank you for providing FACTS that support georgejjl 11/23/14 11:23:00 AM
#79277   Apparently no one here agrees with you're position Apparition 11/23/14 11:20:01 AM
#79276   I don't think the timing of uplist matters frrol 11/23/14 11:15:04 AM
#79275   abiogenesis does not get the ecclesiastical credit it deserves! BIzzy 11/23/14 11:10:16 AM
#79274   Leo and Dr. Menon would not spend the JPsooner 11/23/14 11:09:42 AM
#79273   Monotherapy could be more effective against certain types Apparition 11/23/14 10:59:13 AM
#79272   I agree that the weekend "single agent" debate Darwinian 11/23/14 10:19:04 AM
#79271   i'm thinking!! i'm thinking !!!! about what dr govorchin 11/23/14 10:16:53 AM
#79270   Apparently no on here can refute the following georgejjl 11/23/14 10:12:00 AM
#79269   I think God might approve this sentiment..well said! BIzzy 11/23/14 10:11:05 AM
#79268   The most interesting point in that exchange for Ultimate01 11/23/14 09:58:27 AM
#79267   Folks should focus analysis on ffrol's post IMO. faraifarai 11/23/14 09:33:49 AM
#79266   Good Morning, World Good Morning, CTIX! Everyone have smitter 11/23/14 09:18:13 AM
#79265   Go Wild! Go Menon! TheDane 11/23/14 08:46:11 AM
#79264   You are probably right about that. He Ultimate01 11/23/14 08:43:48 AM
#79258   Frrol - thanks for the link - interesting Amatuer17 11/23/14 07:09:10 AM
#79256   Sox Apparently you are new to this topic. georgejjl 11/23/14 06:08:33 AM
#79255   The only argument that makes sense to me BooDog 11/23/14 05:06:47 AM
#79254   Youssef, nice to see another Bostonian on this sox040713 11/23/14 01:55:11 AM
#79253   If Dr. Menon does not believe Kevetrin can sox040713 11/23/14 01:47:41 AM
#79252   George why don t you email him youssef 11/23/14 01:37:36 AM
#79251   Sox I am from Boston too and I youssef 11/23/14 01:35:06 AM
#79250   Interesting dialogue with good points from Matija and biodoc 11/23/14 01:11:59 AM
#79249   Interesting comment exchange on this SA article: frrol 11/22/14 11:28:17 PM
#79248   Looks like Soligenix's OM compound Phase 2 is frrol 11/22/14 11:24:51 PM
#79247   Well said. This is the best post of Ultimate01 11/22/14 10:42:13 PM
#79246   Friend, you act as if you knew everything djs7 11/22/14 10:36:02 PM
#79245   Can't wait. Happy T-Day. Apparition 11/22/14 08:21:01 PM
#79244   Breaking Cellceutix PR news Dr George, there is etradeedge 11/22/14 08:08:28 PM
#79243   If you only acre about Dr. Krishna Menon georgejjl 11/22/14 07:57:07 PM
#79242   cmon george!!!!!...Hard for me to accept your argument BIzzy 11/22/14 07:54:04 PM
#79241   There is only one set of opinions I etradeedge 11/22/14 07:45:55 PM
#79240   LOL, by June 2015 after the Annual ASCO georgejjl 11/22/14 07:31:22 PM
#79239   LOL. I don't recall that being the issue Apparition 11/22/14 07:16:21 PM
#79238   Obviously, the new COO was misquoted. georgejjl 11/22/14 07:10:11 PM
#79237   The only explanations that I can think of loanranger 11/22/14 07:08:48 PM
PostSubject